FGFR1 amplification predicts poor prognosis in NSCLC early -
By Laura Cowen, medwireNews Reporter
Amplification of receiver fibroblast growth factor 1 ( FGFR1 ) is associated with poor clinical outcomes in patients with non-small cell lung cancer at an early stage (NSCLC), Swiss researchers report.
fluorescenceCoya Tapia, of the University of Berne, and his colleagues used in situ hybridization to measure FGFR1 amplification in tissue samples from 329 patients with early stage (IA- IIB), lymph node NSCLC treated with curative surgery.
They chose to investigate this marker as it has recently been described as "a promising predictive marker for the treatment of anti-FGFR inhibitor."
as shown in the British Journal of Cancer , the overall prevalence of FGFR1 amplification was 12.5% and was significantly higher in samples from 169 patients with squamous cell carcinoma ( CSC) than those taken from 137 patients with adenocarcinoma and 23 patients with large cell carcinoma (20.7 vs 2.2 and 13.0%, respectively).
FGFR1 amplification has increased significantly with the increase in the category T, and was not detected in any samples 36 classified as T1. FGFR1 amplification was also associated with larger tumor size and higher tumor stage.
This conclusion contradicts a hypothesis earlier than FGFR1 amplification is a mutation of the pilot, the researchers note. They suggest, instead, that the amplification is a mutation of the passenger who is subsequently acquired during tumor growth.
Tapia and team also found that FGFR1 amplification occurred mainly in male smokers or former smokers. They say this is surprising because most CSC are diagnosed in men with a history of smoking. "That smoking causes FGFR1 changes or smoking and FGFR1 changes are independent and combined trigger tumorigenesis in NSCLC should be determined in future studies," they note.
patients FGFR1 amplification was overall survival and disease-free survival significantly worse than without it, at a median of 43.9 compared to 103.1 months and 22, 5 compared to 52.4 months, respectively.
Furthermore, multivariate analysis adjusted for smoking, the size of the tumor and the stage of pathological tumor confirmed that FGFR1 amplification was independently associated with prognosis. Indeed, those with amplification were twice as likely to die during follow-up than those without it.
When the researchers looked specifically at CSC, they observed overall survival significantly worse among tumors with FGFR1 amplification during the first 4 years but no significant difference after this time, perhaps because all patients FGFR1 aggressive tumor -amplified died early, they suggest.
Tapia and co-authors conclude that, while FGFR1 amplification seems to be a prognostic marker in early-stage NSCLC, further studies are needed to determine its value as a marker predictive for targeted therapy or adjuvant therapy.
Licensed to medwireNews permission of Springer Healthcare Ltd. © Springer Healthcare Ltd. All rights reserved. None of these parties endorse or recommend any commercial products, services or equipment.
EmoticonEmoticon